Judging from the surge of activities related to the Royalty Pharma plc (NASDAQ:RPRX), this biotech company has garnered attention for various reasons. Jim Cramer mentioned that Royalty Pharma is an excellent company. The company's EVP, Terrance Coyne, and Marshall Urist have sold significant amounts in shares. Furthermore, distinct entities such as Homestead Advisers Corp and AE Wealth Management LLC have reportedly trimmed their holdings in the company, while others like C WorldWide Group Holding A S and Mirae Asset Global Investments Co. Ltd. have increased their stake.
In other news, the company is steadily gaining recognition by hitting a new 1-year high on the NASDAQ. More importantly, Royalty Pharma announced an increase in its dividend from a strong revenue guidance for 2025 and achieved its major buyback. There are varied opinions ranging from the stock being undervalued to questions around its recent outperformance. The biotech company recently struck a funding partnership worth $2 billion with Revolution Medicines, which appears to be attracting fresh attention. Finally, Royalty Pharma has experienced a significant 56.7% rally in 2025.
Royalty Pharma Stocks News Analytics from Sun, 06 Jul 2025 07:00:00 GMT to Fri, 06 Feb 2026 13:21:04 GMT - Rating 7 - Innovation -2 - Information 6 - Rumor -1
